Related by context. All words. (Click for frequent words.) 79 IMC A# 75 human IgG1 monoclonal 73 Archexin 72 alvespimycin 72 HGS ETR2 72 Phase #b/#a clinical 72 antibody MAb 71 HCD# [002] 71 drug conjugate 71 Advaxis Phase 71 PEG SN# 71 IMA# 71 HGS ETR1 71 HGS# 71 CYT# potent vascular disrupting 70 PSMA ADC 70 JAK2 inhibitor 70 investigational humanized monoclonal antibody 70 Trastuzumab DM1 70 investigational monoclonal antibody 70 Daclizumab 70 Phase Ib II 70 HuLuc# 70 ganetespib 70 oral prodrug 70 phase IIb clinical 70 tanespimycin 69 Panzem R NCD 69 Aplidin R 69 MAGE A3 ASCI 69 TOCOSOL Paclitaxel 69 IgG1 monoclonal antibody 69 elotuzumab 69 ARRY # 69 XL# XL# 69 deforolimus 69 candidate CRLX# 69 Quinamed 69 evaluating satraplatin 69 Aflibercept 69 MKC# MT 69 ASONEP 69 Elotuzumab 69 VitiGam 69 Phase IIb clinical trials 69 IAP inhibitor 69 Angiocept 69 Aurora kinase inhibitor 69 enzastaurin 68 Phase #b/#a 68 XL# XL# XL# XL# 68 oral picoplatin 68 pertuzumab 68 PrevOnco 68 SAR# [004] 68 LymphoStat B TM 68 phase IIb trial 68 IL# PE#QQR 68 mertansine 68 Exelixis compounds 68 Omacetaxine 68 XmAb# 68 novel VDA molecule 68 including eniluracil ADH 68 JAK1 68 YONDELIS 68 BRIM2 68 MGd 68 PI3K/Akt pathway inhibitor 68 phase IIa clinical 68 Allovectin 7 68 NPC 1C 68 Blinatumomab 68 mapatumumab 68 Tesetaxel 68 orally administered inhibitor 68 PrevOnco ™ 68 trastuzumab DM1 T DM1 68 tramiprosate Alzhemed TM 68 AQ4N 68 Phase 2b Clinical Trial 68 therapeutic monoclonal antibody 68 BZL# 68 IAP inhibitors 68 Bezielle 68 evaluating tivozanib 68 PSN# [002] 68 GVAX ® 68 PDE4 inhibitor 68 ALN TTR 67 lintuzumab 67 Cloretazine ® 67 dacetuzumab 67 BAY #-# 67 EndoTAG TM -1 67 Immunotherapeutic 67 Enzastaurin 67 AKT inhibitor 67 Sapacitabine 67 fosbretabulin 67 CRLX# 67 PLK1 SNALP 67 ZK EPO 67 TACI Ig 67 anti EGFR antibody 67 MKC# MKC# PP 67 Personalized Immunotherapy 67 INCB# [001] 67 FOLOTYN ® 67 DPX Survivac 67 Tarvacin TM 67 DCVax R 67 immatics 67 registrational 67 Phase Ib clinical 67 OvaRex R 67 novel tubulin binding 67 LymphoStat B belimumab 67 oral ridaforolimus 67 OMP #M# 67 INS# [001] 67 humanised monoclonal antibody 67 OXi# 67 AAG geldanamycin analog 67 OncoVex 67 Pimavanserin 67 therapeutic monoclonal antibodies 67 midstage clinical 67 Sym# 67 ALN VSP Phase 67 Phase IIb trials 67 adecatumumab MT# 67 Ocrelizumab 67 romazarit 67 Solazed TM 67 ASG 5ME 67 Virulizin ® 67 MT#/MEDI-# 67 SUCCEED trial 67 obatoclax 67 tubulin inhibitor 67 Phase III Pivotal 67 TKB# 67 PANVAC VF 67 multitargeted 67 Insegia 67 PXD# 67 Aplidin 67 Bicifadine 67 Azedra 67 Exherin TM 67 liposomal formulation 67 HCV polymerase 67 ONCONASE R 67 Factor VIIa 67 humanized antibody 67 MEK inhibitors 67 HGS ETR1 mapatumumab 67 Annamycin 67 vidofludimus 67 rALLy clinical trial 67 targeting CD# 67 tiapamil 67 TRX1 67 CCX# 67 tezampanel NGX# 67 HuMax EGFr 67 BiTE R 67 receptor tyrosine kinase inhibitor 67 Proxinium TM 66 PNP inhibitor 66 ZOLINZA 66 otelixizumab 66 Phase #b/#a trial 66 XmAb 66 Tyrima 66 huC# DM4 66 Golimumab 66 targeted radiotherapeutic 66 cellular immunotherapy 66 Aurora Kinase 66 accumulate preferentially 66 investigational therapies 66 Curaxin CBLC# 66 subcutaneous formulation 66 SAR# [002] 66 Pivotal Phase 66 forodesine 66 lintuzumab SGN 66 DermaVir Patch 66 GLP toxicology studies 66 Antibody Drug Conjugate 66 novel therapeutic antibodies 66 Uvidem 66 multicenter Phase II 66 docetaxel Taxotere R 66 AEG# 66 Phase 1b clinical trials 66 Trofex 66 ZACTIMA 66 Squalamine 66 myelofibrosis polycythemia vera 66 nucleoside analog 66 HER pathway 66 docetaxel Taxotere ® 66 chimeric monoclonal antibody 66 siRNA therapeutic 66 SinuNase ™ 66 Telatinib 66 histone deacetylase inhibitor 66 initiated Phase 1b 66 Troxatyl 66 RGB # 66 sunitinib malate 66 Xanafide 66 Xcellerated T Cells 66 THR beta agonist 66 ISTODAX 66 trastuzumab DM1 66 Curaxin 66 GRN# 66 XL# anticancer compounds 66 PF # [002] 66 Chemophase 66 CYC# 66 radiation sensitizer 66 IgG1 antibody 66 Alfimeprase 66 demonstrated antitumor activity 66 apoptosis inducer 66 MyVax R 66 Pralatrexate 66 Lenocta 66 Vandetanib 66 oral deforolimus 66 MGCD# [001] 66 Deforolimus 66 Temsirolimus 66 Ceflatonin 66 Hedgehog Pathway Inhibitor 66 HuMax CD# 66 axitinib 66 Completes Patient Enrollment 66 MEK Inhibitor 66 Pertuzumab 66 non nucleoside inhibitor 66 Bayer HealthCare Onyx Pharmaceuticals 66 Neuvenge 66 volociximab 66 vascular disrupting agents 66 HCV protease inhibitor 66 CR# vcMMAE 66 budesonide foam 66 Panzem ® 66 Potelligent Technology 66 ovarian prostate 66 Rigel R# 66 neratinib 66 Phase 1a clinical 66 telomerase therapeutic 66 MAXY alpha 66 lumiliximab 66 Saxagliptin 66 Phase Ib clinical trials 66 Vitaxin 66 BRAF inhibitor 66 seliciclib CYC# 66 farletuzumab 66 VEGFR2 inhibitor 66 R#/MEM # 66 BiTE 66 TKM ApoB 66 Initiates Phase III 66 recurrent metastatic ovarian cancer 66 small molecule tyrosine 66 ALN PCS 66 cilengitide 66 Phase IIb III 66 TMC# [002] 66 erlotinib Tarceva ® 66 IIb clinical trial 65 compound INCB# 65 Cetrorelix 65 vosaroxin 65 BRIM3 65 antibody MT# 65 RhuDex R 65 Evoltra ® 65 cMET 65 Panitumumab 65 EOquin 65 paclitaxel Taxol ® 65 Initiate Phase 65 dasatinib Sprycel ® 65 dasatinib Sprycel 65 OncoVEX 65 immunotherapeutic vaccine 65 targeted antifolate 65 OncoVEX GM CSF 65 KRN# 65 Pivotal Phase III 65 EP #R 65 vemurafenib 65 Phase IIIb clinical 65 multicenter Phase 65 metastatic hormone refractory 65 Tykerb lapatinib 65 OMP #R# 65 Fx #A 65 Cloretazine 65 APEX PD 65 Panzem NCD 65 Phase 2a Clinical Trial 65 Initiates Phase II 65 virus HCV protease inhibitor 65 Nanobody 65 ixabepilone 65 Litx 65 metastatic colorectal 65 SNT MC# 65 proteasome inhibitor 65 CEQ# 65 hypoxia activated prodrug 65 Phase Ib study 65 CD# CEA 65 PDE# inhibitors 65 PNT# 65 Teplizumab 65 investigational pan BCR 65 PRECISE Trial 65 Romidepsin 65 refractory chronic lymphocytic 65 JAK3 65 humanized monoclonal antibody 65 ATL# [001] 65 RELOVAIR ™ 65 acyclovir Lauriad R 65 multi kinase inhibitor 65 CCR9 antagonist 65 Exelixis XL# 65 gefitinib Iressa 65 CD4 monoclonal antibody 65 phase IIb 65 epothilone 65 sorafenib tablets 65 cannabinor 65 Velcade bortezomib 65 oncolytic virus therapies 65 refractory metastatic 65 Zolinza 65 Tanespimycin 65 Intravenous CP 65 selective modulator 65 bardoxolone 65 valopicitabine NM# 65 Panzem R 65 eniluracil 65 anticancer compound 65 Cloretazine R 65 telomerase inhibitor drug 65 GW# [003] 65 Phase #/#a trial 65 Gleevec resistant 65 midstage trials 65 galiximab 65 Ixempra 65 Phase 1b 65 apoptosis proteins 65 personalized immunotherapy 65 epigenetic therapies 65 DAVANAT 65 pharmacokinetic PK study 65 Genz # 65 phase Ib clinical 65 relapsed leukemia 65 AGS PSCA 65 agonistic human 65 Symadex 65 Onconase 65 dose escalation clinical 65 PHX# 65 Davanat 65 kidney urologic 65 registrational trials 65 MCSP respectively 65 Dapagliflozin 65 Ridaforolimus 65 RAV# 65 Belinostat 65 RhuDex TM 65 ThermoDox ® clinical 65 SUTENT ® 64 dextromethorphan quinidine 64 trial evaluating PRX# 64 TOCOSOL Camptothecin 64 HepeX B 64 PEG Interferon lambda 64 LEP ETU 64 vascular disrupting agent 64 lymphoid malignancies 64 CBLC# 64 sapacitabine CYC# 64 StemEx 64 triggers apoptosis programmed 64 LUMINATE 64 selective S#P# receptor agonist 64 Zenvia ™ 64 mda 7 64 PDX pralatrexate 64 TOCOSOL 64 systemic anaplastic large 64 recurrent glioblastoma multiforme 64 Tumour Vascular Disrupting Agent 64 ALN VSP 64 TBC# 64 Erbitux cetuximab 64 Akt inhibitor 64 G#DT 64 dimebon latrepirdine 64 ularitide 64 ADP receptor antagonist 64 metaglidasen 64 BLA filing 64 Urocortin 2 64 HuMax CD4 64 PI3K/mTOR 64 RhuDex ® 64 Multiple Ascending Dose 64 Surfaxin LS 64 Phase lll 64 MEND CABG II 64 cathepsin K inhibitor 64 Fc fusion protein 64 Achieves Primary Endpoint 64 Eniluracil 64 Seliciclib 64 Stimuvax R 64 trastuzumab Herceptin R 64 Vicriviroc 64 DEB# 64 Neulasta ® 64 YONDELIS R 64 GRNVAC1 64 Hsp# Inhibitor 64 cardio renal 64 Anticalin 64 ARIKACE ™ 64 cetuximab Erbitux ® 64 elacytarabine 64 cetuximab Erbitux 64 L BLP# 64 MKC# 64 selective androgen receptor modulator 64 LHRH receptor positive 64 MAb 64 phase Ib 64 Phase Ib IIa 64 relapsed refractory multiple myeloma 64 Mipomersen 64 Phase 2a clinical trials 64 GALNS 64 Reports Preclinical Data 64 CDK cyclin dependent 64 MORAb 64 PRECISE trial 64 MDS AML 64 omacetaxine mepesuccinate 64 ALTROPANE R 64 alpha folate receptor 64 Voreloxin 64 JZP 64 Allovectin 7 R 64 MOZOBIL 64 Meets Primary Endpoint 64 Phase 2b clinical trials 64 R roscovitine 64 CORT # 64 pivotal bioequivalence 64 Phase IIB 64 OHR/AVR# 64 Phase IIa trials 64 Kinase Inhibitor 64 AP# [003] 64 Asentar 64 Xcytrin R 64 Talabostat 64 antisense inhibitors 64 Azacitidine 64 drug pipeline TAFA# 64 ALN HTT 64 CB2 selective receptor agonist 64 Cannabinor 64 novel peptide 64 monoclonal antibody IgG1 Mab 64 darapladib 64 reslizumab 64 registrational trial 64 Hepatocellular Carcinoma HCC 64 HDACi 64 relapsed MM 64 JAK inhibitor 64 orally bioavailable 64 cediranib 64 potent cytotoxic 64 Zybrestat 64 XOMA 3AB 64 Trastuzumab 64 CA4P 64 HDAC Inhibitor 64 daclizumab 64 orally dosed 64 regorafenib 64 Phase 2a trial 64 A3 adenosine receptor 64 IRX 2 64 ALN HPN 64 rxRNA 64 initiate Phase 1b 64 #D#C# 64 Selective Electrochemical Tumor Ablation 64 Aurora kinase 64 oral PTH 64 Ceflatonin R 64 MEK inhibitor 64 CCR5 mAb 64 Sudhir Agrawal D.Phil 64 oral nucleoside analogue 64 velafermin 64 Gamunex C 64 gastro intestinal inflammation 64 TAFA# 64 TLK# 64 brivanib 64 ChronVac C R 64 JAK2 Inhibitor 64 Tocosol Paclitaxel 64 HER1 64 TransVax 64 EndoTAG 63 nilotinib Tasigna ® 63 dirucotide MBP# 63 Tarceva TM 63 BRAF mutant 63 generation purine nucleoside 63 TBC M4 63 R sorafenib tablets 63 Imprime PGG 63 BrachySil TM 63 Tesmilifene 63 Prodarsan R 63 novel immunotherapies 63 JAK inhibitors 63 ocrelizumab 63 preclinically 63 Hematide ™ 63 EGS# 63 synthetic retinoid 63 ORENCIA R 63 ENMD # 63 rALLy trial 63 CD# antibody [001] 63 novel emulsion formulation 63 immunotherapeutic agent 63 entinostat 63 sorafenib Nexavar 63 Novolimus 63 Guanilib 63 Ozarelix 63 HER2 positive metastatic breast 63 Phase 2b Trial 63 Randomized Phase II 63 TELINTRA 63 gemcitabine Gemzar ® 63 JAK2 inhibitors 63 class mGluR5 inhibitor 63 Antiangiogenic 63 CIMZIA TM 63 Zemiva TM 63 dose escalation Phase 63 immune modulating 63 glucokinase activator 63 aurora kinase 63 dacetuzumab SGN 63 ApoB SNALP 63 Combination REOLYSIN R 63 Entry Inhibitor 63 ospemifene 63 potent antiproliferative 63 HCV polymerase inhibitors 63 lenalidomide Revlimid R 63 IMiDs ® 63 Avastin adjuvant 63 TELCYTA 63 ALN TTR# 63 IIa trial 63 Ofatumumab 63 phase IIa 63 Thiovir 63 Vectibix panitumumab 63 SinuNase TM 63 MyVax ® 63 Lovaxin C 63 Randomized Phase 63 Cethromycin 63 Phase IIb Trial 63 incyclinide 63 K ras mutations 63 Cloretazine R VNP#M 63 tesmilifene 63 torezolid phosphate 63 selective kinase inhibitor 63 hormone LHRH antagonist 63 Phenoptin 63 GED aPC 63 Phase IIb Clinical Trial 63 severe hypercholesterolemia 63 motesanib 63 HepeX B TM 63 Specifid 63 celgosivir 63 Glufosfamide 63 Ixabepilone 63 investigational compounds 63 Pradefovir 63 novel immunotherapeutic 63 Amrubicin 63 Tezampanel 63 EVIZON TM 63 Safinamide 63 Presents Preclinical Data 63 XL# SAR# 63 BLP# Liposome Vaccine 63 ELACYT 63 Optiquel ™ 63 non nucleoside HCV 63 metastatic sarcomas 63 signal transduction inhibitors 63 HuMax 63 cystinosis patients 63 huN# DM1 63 UPLYSO 63 ofatumumab HuMax CD# 63 vinca alkaloid 63 investigational hepatitis C 63 blinded randomized placebo controlled 63 octreotide implant 63 Maribavir 63 trastuzumab Herceptin 63 XP# XP# 63 pediatric acute lymphoblastic 63 anti CTLA 63 sodium thiosulfate STS 63 preclinical toxicology 63 MIST II 63 cancer immunotherapies 63 oral proteasome inhibitor 63 OvaRex ® MAb 63 HDL Selective Delipidation 63 leading oral taxane 63 T DM1 63 Talotrexin 63 MOR# 63 PhG alpha 1 63 evaluating Actimmune 63 Spiegelmer ® 63 Allovectin 7 ® 63 alemtuzumab Campath 63 Degarelix 63 cetuximab Erbitux R 63 E1 INT TM 63 Campath alemtuzumab 63 protein kinase inhibitor 63 Cardiotoxicity 63 cutaneous T 63 Vaccinex 63 SPRYCEL ® 63 R#/MEM 63 NOX E# 63 Aganocide 63 thalidomide Thalomid 63 Epratuzumab 63 soluble tumor necrosis 63 5 fluorouracil leucovorin 63 NTDDS 63 lorcaserin Phase 63 Dendreon Provenge 63 investigational immunotherapy 63 tafamidis 63 Elagolix 63 bortezomib Velcade R 63 triphendiol 63 Abiraterone acetate 63 Synavive 63 Virulizin R 63 bevacizumab Avastin ® 63 evaluating T DM1 63 MAXY G# 63 Myocet 63 Phase III Clinical Trial 63 PLX# 63 refractory colorectal cancer 63 PGL# 63 Proellex TM 63 apricitabine ATC 63 Initiates Clinical 63 Nexavar ® 63 COSIRA trial 63 Traficet EN 63 HQK 63 Prednisporin 63 orBec 63 Chimigen TM 63 Epothilone D 63 NS5A 63 systemic RNAi therapeutic 63 pancreatic colon 63 plus dacarbazine 63 TRACON Pharmaceuticals 63 interferon gamma 1b 63 Solazed 63 candidate deforolimus 63 pan HDAC inhibitor 63 Kosan dependence 63 Amigal 63 OncoGel 63 Dacogen injection 63 oral methylnaltrexone 63 Initiate Clinical Trial 63 novel anticancer 63 evaluating mipomersen 63 midstage studies 63 Presents Preclinical 63 selectin antagonist 63 Begins Dosing 63 Metastatic Melanoma 63 P#X# antagonist 63 tezampanel 63 PKC# 63 bavituximab monotherapy trial 63 Telintra 63 Laquinimod 63 essential thrombocythemia ET 63 Hsp# inhibition 63 CINTREDEKIN BESUDOTOX 63 immunological diseases 63 ongoing Phase 1b 63 NABTT 63 XL# XL# XL# 63 anticancer therapeutics 63 monoclonal antibody mAb 63 AE# vaccine 63 small molecule agonists 63 Anticalins R 63 TransVax ™ 63 GV# [001] 63 HuMax TAC 63 HIV integrase inhibitors 63 talabostat 63 ESBA# 63 tumor vascular disrupting 63 LUX Lung 63 BioNumerik 63 ® bortezomib 63 VEGF inhibitors 63 Urocidin 63 RIGScan CR 63 blood clot dissolver 63 AEGR 63 bortezomib Velcade 63 Crofelemer budesonide foam 62 GeneICE 62 Nanobody ® 62 TELINTRA R 62 drug conjugate ADC 62 TKM PLK1 62 TNFerade TM 62 Phase Ib 62 mGluR2 NAM 62 ridaforolimus 62 RhuDex 62 Liprotamase 62 Albuferon TM 62 FOLFOX6 chemotherapy regimen 62 immunomodulator 62 M# rationally 62 Aeolus Pharmaceuticals Announces 62 PSN# [001] 62 BHT DNA 62 Allovectin 7 r 62 hepatitis C HCV 62 NS5b 62 MDV# 62 biologic therapeutics 62 lapatinib Tykerb 62 NS#/#A protease 62 GSK # 62 radiolabeled TM# 62 refractory CLL 62 Dextofisopam 62 brentuximab vedotin SGN 62 lung pancreatic 62 Tarvacin 62 antisense drug 62 Genasense oblimersen sodium Injection 62 IMPDH inhibitor 62 Vaxfectin ® 62 Alzhemed TM 62 CD# monoclonal antibody 62 EGFR HER2 62 Initiates Enrollment 62 ThermoDox R 62 Simulect 62 IND submission 62 VNP#M 62 immune stimulatory 62 Phase #/#a 62 Brentuximab Vedotin SGN 62 peptibody 62 SYN# 62 biliary tract cancer 62 Otelixizumab 62 recurrent NSCLC 62 randomized controlled Phase 62 initiated Phase Ib 62 mitogen activated ERK kinase 62 ASA# 62 DCCR 62 INSPIRE Trial Phase III 62 Fludara ® 62 CHAMPION PCI 62 randomized Phase IIb 62 Nasulin ™ 62 rALLy 62 GMX# 62 Alemtuzumab 62 HCV protease inhibitors 62 LHRH antagonists 62 HyperAcute 62 Oral NKTR 62 Nicole Onetto MD 62 selective orally bioavailable 62 IMiDs R 62 oral taxane 62 phase IIb III 62 PEGylated interferon 62 Tarvacin Anti Viral 62 Sopherion 62 Phase IIa trial 62 EndoTAGTM 1 62 Phase 1b trial 62 AIMM trial 62 Adenosine Therapeutics 62 FGFR 62 thymalfasin 62 Initiates Phase 2b 62 paclitaxel poliglumex 62 recombinant polyclonal antibody 62 recombinant PSMA vaccine 62 autologous cellular immunotherapy 62 phase IIb study 62 riociguat 62 DXL# 62 CoFactor 62 Onalta ™ 62 Alvine Pharmaceuticals 62 tremelimumab 62 next generation URAT1 62 unique alkylating agent 62 PORxin TM 62 recurrent glioma 62 ART# 62 Phase 1b Clinical Trial 62 Saforis 62 personalized cellular immunotherapy 62 Pazopanib 62 recombinant biopharmaceutical 62 angiogenesis inhibitor 62 GLPG# 62 CMV vaccine 62 CCR5 antagonist 62 chemotherapy FOLFOX 62 immunotoxin 62 Tyrosine Kinase Inhibitor 62 MYDICAR ® 62 nucleoside reverse transcriptase inhibitor 62 DiaPep# 62 Hormone Refractory Prostate Cancer 62 Peginterferon alfa 2b 62 ADVEXIN p# therapy 62 TYZEKA 62 metastatic castrate resistant 62 M2 subunit 62 candidates Azedra TM 62 GATTEX ™ 62 antiangiogenic agents 62 recombinant adeno associated 62 UVIDEM 62 alagebrium 62 relapsed multiple myeloma 62 Tarvacin Anti Cancer 62 Genasense ® 62 vaccine GRNVAC1 62 LAB CGRP 62 EnVivo Pharmaceuticals 62 Marqibo TM 62 uric acid lowering 62 rindopepimut 62 AS# amonafide L malate 62 LibiGel Phase III 62 castrate resistant prostate cancer 62 Locked Nucleic Acid 62 PORxin TM platforms 62 ZYBRESTAT fosbretabulin 62 NASDAQ ABII 62 novel peptides 62 adalimumab Humira 62 Fc engineered 62 AeroLEF TM 62 Albuferon Phase 62 Anti VEGF 62 Smac mimetics 62 OMNARIS HFA 62 PROSTVAC VF 62 REG2 62 Interferon beta 1a 62 ruxolitinib 62 TRO# 62 Onconova 62 Zemplar Capsules 62 BiTE ® 62 BR.# 62 Ataluren 62 Ophthotech 62 FLT3 62 sapacitabine 62 APPRAISE 62 GAP #B# 62 Herceptin trastuzumab 62 ISF# 62 visilizumab 62 zanolimumab 62 anticancer therapy 62 isoform selective 62 oral ghrelin agonist 62 GATTEX ® 62 Nexavar sorafenib 62 glucagon receptor 62 Celator 62 modified glutathione analog 62 ALK inhibitor 62 Arranon 62 HSP# inhibitor 62 trastuzumab emtansine T DM1 62 alpha antagonist 62 vivo validation 62 tasimelteon 62 cabozantinib 62 LBH# 62 Therapeutic Vaccine 62 TG# [003] 62 relapsed ovarian cancer 62 selective inhibition 62 Trofex TM 62 chemokine receptor 62 NU# direct 62 INxin 62 Nuvion 62 preclinical efficacy 62 NP2 Enkephalin 62 CD# expressing 62 investigational protease inhibitor 62 predictive biomarkers 62 confirmatory Phase III 62 Pruvel 62 TransVax tm 62 Sphingomab TM 62 developed preclinically 62 anti CD# antibodies 62 GSK '# 62 Bendamustine 62 omega interferon 62 mGluR5 NAM 62 liposomal doxorubicin 62 oral Janus kinase 62 oral talactoferrin 62 TransVax TM 62 Temodar ® 62 DCVax ® Brain 62 beta 1a 62 humanized monoclonal antibodies 62 vinorelbine tartrate 62 treatment naive genotype 62 Alocrest 62 VALOR trial 62 Anavex #-# 62 LHRH antagonist 62 Granulocyte Colony Stimulating Factor 62 anti CD# monoclonal 62 squalamine